Egetis Therapeutics First Quarter 2024 Earnings: Beats Expectations

Egetis Therapeutics (STO:EGTX) First Quarter 2024 Results

Key Financial Results

• Revenue: kr12.1m (up 78% from 1Q 2023).
• Net loss: kr75.0m (flat on 1Q 2023).
• kr0.26 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Egetis Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%.

Looking ahead, revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 13% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Egetis Therapeutics (1 doesn't sit too well with us!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.